ABSTRACT
This study aimed to analyze the efficacy of the monoclonal antibodies ipilimumab, nivolumab, and pembrolizumab when compared with conventional chemotherapy in the treatment of advanced melanoma. Three authors made the search independently and five articles matched the eligibility criteria. A fourth expert confirmed their quality (κâ¯=â¯1). The meta-analysis for overall survival and 12-month overall survival was impaired due to remarkably high heterogeneity (I2â¯=â¯91 % and 86 %, respectively). However, chemotherapy showed benefits on 24-months overall survival (RRâ¯=â¯1.60; IC95 %: 1.29, 1.98; pâ¯<â¯0.0001). The interruption by toxicity outcome showed no significant differences between therapies. Some studies used monoclonal antibodies in monotherapy or in combination and some groups of participants showed heterogeneity, which made the analysis difficult. Given the exorbitant costs of monoclonal antibodies in low and middle-income countries, the evidence of its benefits is limited when considering the replacement of conventional therapy with immunotherapy in public health systems.
